Editorial: Medical cannabis - Progress and promise

Duns, Glenn

doi:10.31128/ajgp-06-21-1234e

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,9 Many have legitimate lived experience of lasting pain reduction with cannabis that is not easily disregarded. 7,78,79 There is clearly a disconnection between the pronouncements of specialist medical colleges and current prescribing and community use of cannabinoids in Australia. It is hoped that the results of the next generation of clinical trials of cannabinoid products and pain will help to resolve this tension.…”

Section: Discussionmentioning

confidence: 99%

Medicinal cannabis in the treatment of chronic pain

Henderson¹,

Kotsirilos²,

Cairns³

et al. 2021

Aust J Gen Pract

View full text Add to dashboard Cite

BackgroundChronic pain is a major health issue, adversely affecting millions of Australians and costing billions of dollars annually. Current pharmaceutical treatments may be limiting, and in some cases ineffective, while carrying substantial liabilities. Medicinal cannabis is an increasingly popular, albeit controversial, alternative. Medicinal cannabis in the treatment of chronic painMedicinal cannabis in the treatment of chronic pain Clinical

show abstract

Section: Discussionmentioning

confidence: 99%

Medicinal cannabis in the treatment of chronic pain

Henderson¹,

Kotsirilos²,

Cairns³

et al. 2021

Aust J Gen Pract

View full text Add to dashboard Cite

show abstract

“…Cannabis rich in THC is the most frequently consumed illicit substance worldwide 9 ; however, legalization efforts for medical and recreational use have been on the increase, particularly in recent years. [10][11][12][13] Often products low in THC can be legally purchased. 14,15 For instance, under current Swiss law, cannabis flowers containing less than 1% THC are not banned under the narcotics law.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Quantitative determination of five cannabinoids in blood and urine by gas chromatography tandem mass spectrometry applying automated on‐line solid phase extraction

Frei

Frauchiger

Scheurer

et al. 2022

Drug Testing and Analysis

View full text Add to dashboard Cite

Cannabis is the most frequently consumed illegal substance worldwide. More recently, an increasing number of legal cannabis products low in psychoactive Δ 9 -tetrahydrocannabinol (THC) but high in non-intoxicating cannabidiol (CBD) are being more widely consumed. While the detection and quantification of THC and its metabolites in biological matrices is an important forensic-toxicological task, additional detection of CBD is also important, for example, when examining the plausibility of consumer's statements. This report describes the method validation for the quantitative determination of THC and its two major metabolites, 11-hydroxy-THC (OH-THC) and 11-nor-9-carboxy-THC (THC-COOH), as well as CBD and cannabinol (CBN) in whole blood and urine. The method employs automated on-line solid phase extraction coupled to gas chromatography tandem mass spectrometry (GC-MS/MS). The method was fully validated according to guidelines of the Swiss Society of Legal Medicine (SGRM) and the Society of Toxicological and Forensic Chemistry (GTFCh). The method fulfilled the validation criteria regarding analytical limits, accuracy and precision, extraction efficacy, and sample stability. The limits of detection (LODs) in whole blood and urine were 0.15 ng/mL for THC, OH-THC and CBD, 0.1 ng/mL for CBN, and 1.0 ng/mL for THC-COOH. The limits of quantification (LOQ) in whole blood and urine were 0.3 ng/mL for THC, OH-THC and CBD, 0.2 ng/mL for CBN, and 3.0 ng/mL for THC-COOH. The fully validated and automated method allows sensitive and robust measurement of cannabinoids in whole blood and urine. Detection of CBD provides additional information regarding consumed products. K E Y W O R D S cannabinoids, driving under the influence of drugs, GC-MS/MS, on-line solid phase extraction Correction added on April 22, 2022, after first online publication: CSAL funding statement has been added.

show abstract

Editorial: Medical cannabis - Progress and promise

Cited by 2 publications

References 3 publications

Medicinal cannabis in the treatment of chronic pain

Medicinal cannabis in the treatment of chronic pain

Quantitative determination of five cannabinoids in blood and urine by gas chromatography tandem mass spectrometry applying automated on‐line solid phase extraction

Contact Info

Product

Resources

About